Edition:
United States

Express Scripts Holding Co (ESRX.O)

ESRX.O on Nasdaq

59.76USD
26 May 2017
Change (% chg)

$-0.33 (-0.55%)
Prev Close
$60.09
Open
$60.05
Day's High
$60.33
Day's Low
$59.57
Volume
2,311,990
Avg. Vol
4,892,790
52-wk High
$80.02
52-wk Low
$57.80

Latest Key Developments (Source: Significant Developments)

Express Scripts announces launch ofInside Rx, a new, partially owned subsidiary
Monday, 8 May 2017 08:15am EDT 

May 8 (Reuters) - Express Scripts Holding Co :Express scripts holding - announced launch of inside rx, a new, partially owned unit to expand access to brand and generic medications for patients.  Full Article

Amerisourcebergen reports new 5-year pharmaceutical supply agreement with Express Scripts
Monday, 1 May 2017 06:30am EDT 

May 1 (Reuters) - Amerisourcebergen Corp ::Amerisourcebergen announces new five-year pharmaceutical supply agreement with express scripts.Agreement extends through september 30, 2022.Amerisourcebergen Corp - fiscal year 2016 revenue contribution from that agreement was approximately $23 billion.Amerisourcebergen Corp- amerisourcebergen and express scripts' most recent supply agreement began in oct. 2012 and was set to expire in september 2017.Signed a new five-year agreement to supply pharmaceuticals to express scripts holding company.  Full Article

Express Scripts reports Q1 GAAP earnings per share $0.90
Monday, 24 Apr 2017 04:01pm EDT 

April 24 (Reuters) - Express Scripts Holding Co : :Express Scripts announces 2017 first quarter results; provides update on anthem relationship and visibility into core PBM business excluding contribution from Anthem, Coventry and Catamaran.Q1 adjusted earnings per share $1.33.Q1 GAAP earnings per share $0.90.Q1 earnings per share view $1.32 -- Thomson Reuters I/B/E/S.Sees Q2 2017 adjusted earnings per share $1.70 to $1.74.Express scripts holding co qtrly adjusted claims of 351.7 million, down 1pct.Expects total adjusted claims for Q2 of 2017 to be in range of 343 million to 353 million.Express Scripts Holding Co says qtrly revenue $24.65 billion versus. $24.79 billion last year.Increased its guidance for 2017 adjusted earnings per diluted share to a range of $6.90 to $7.04.Q1 earnings per share view $1.32, revenue view $24.99 billion -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $6.93 -- Thomson Reuters I/B/E/S.Q2 earnings per share view $1.68 -- Thomson Reuters I/B/E/S.Express Scripts Holding - recently told by anthem management that anthem intends to move its business when co's current contract with anthem expires on Dec 31, 2019.Express Scripts Holding Co - anthem is not interested in continuing discussions regarding pricing concessions for 2017-2019.Express Scripts Holding Co - Anthem has "not provided formal written notice that it does not intend to renew its contract with company".  Full Article

Express Scripts reports Q4 GAAP EPS $2.34
Tuesday, 14 Feb 2017 04:22pm EST 

Express Scripts Holding Co : Express scripts announces 2016 fourth quarter and full year results . Q4 GAAP earnings per share $2.34 . Q4 earnings per share view $1.87 -- Thomson Reuters I/B/E/S . Reaffirms FY 2017 adjusted earnings per share view $6.82 to $7.02 . Q4 adjusted earnings per share $1.88 . Express scripts holding co says q4 adjusted claims of 354.9 million, down 6 pct, largely due to roll-off of coventry business . Express scripts holding reaffirms its 2017 adjusted earnings per diluted share guidance in range of $6.82 to $7.02 . Says expects total adjusted claims for Q1 of 2017 to be in range of 345 million to 355 million . Q4 revenue $24.86 billion versus $26.18 billion . Says adjusted earnings per diluted share for Q1 of 2017 is estimated to be in range of $1.30 to $1.34 .Q4 revenue view $26.31 billion -- Thomson Reuters I/B/E/S.  Full Article

Express Scripts Holding announces 2017 savings plan
Monday, 6 Feb 2017 06:00am EST 

Express Scripts Holding Co : Says in 2016, Express Scripts National Preferred Formulary saved plans $1.3 billion .Says Express Scripts National Preferred Formulary is projected to deliver additional $1.8 billion in savings in 2017.  Full Article

Express Scripts says conversation on drug pricing not going away
Wednesday, 14 Dec 2016 11:38am EST 

Express Scripts Holding Co - : Express Scripts says it expects fewer patent expirations in 2017 relative to 2016: conf call . Express Scripts says diabetes care value program will significantly impact anticipated increase in diabetes drug spend in 2017: conf call . Express Scripts is testing asthma remote monitoring solution that combines inhaler sensors, smartphone app, and monitoring from sos center: conf call . Express Scripts CEO says "it's so early but...i've not seen anything that causes me to be hugely concerned" in relation to incoming Trump administration . Express Scripts says has incorporated a "moderate level of inflation" for 2017, says unlikely inflation will represent a significant headwind . Express Scripts says "we've been disciplined with m&a, we've not announced anything, and it's not that we aren't engaged" : conf call . Express Scripts says expects to return the majority of its free cash flow to shareholders in 2017 via share repurchases in the open market: conf call . Express Scripts plans to achieve cost reductions in 2017 resulting in flat to slightly lower SG&A expense in 2017 versus 2016: conf call . Express Scripts says in 2016 it saw greater than 97.5 percent client retention: conf call . Express Scripts says in 2017, it expects to deliver $1.8 billion in client savings from national preferred formulary clients : conf call.  Full Article

Express Scripts Holding announces 2017 financial guidance
Wednesday, 14 Dec 2016 07:00am EST 

Express Scripts Holding Co : Sees total adjusted claims for year ending December 31, 2017 1,375 million to 1,425 million . Express Scripts Holding Company announces 2017 financial guidance . Reaffirms FY 2016 adjusted earnings per share view $6.36 to $6.42 . Sees FY 2017 adjusted earnings per share $6.82 to $7.02 . Sees FY 2016 earnings per share $5.28 to $5.34 . Sees cash flow from operations for year ending December 31, 2017 $4,700 million to $5,200 million . Updating 2016 total adjusted claims guidance from a range of 1,265 million to 1,280 million to a range of 1,400 million to 1,415 million . FY2016 earnings per share view $6.39, revenue view $101.66 billion -- Thomson Reuters I/B/E/S . FY2017 earnings per share view $6.93 -- Thomson Reuters I/B/E/S . Revising methodology for reporting network claims for 2017 guidance, for reporting periods beginning with year ending Dec 31, 2016 .Revised methodology includes adjustment to reflect non-specialty network claims filled through 90-day network programs.  Full Article

Express Scripts chief medical officer says Mylan has a monopoly on the EpiPen
Thursday, 25 Aug 2016 04:03pm EDT 

: Express Scripts Chief Medical Officer Steve Miller On Mylan Epipen Price Hike - "Mylan could lower the price today" . Express Scripts Chief Medical Officer Steve Miller On Mylan Epipen Price Hike - Mylan has a monopoly on the epipen Further company coverage: [MYL.O ESRX.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Horizon pharma says it continues to have discussions with Express Scripts
Monday, 1 Aug 2016 09:01pm EDT 

Horizon Pharma : Continues to have discussions with express scripts and sees potential pathway to completion of potential partnership with express scripts beginning 2017 .Recognizes express scripts published formulary exclusion list, which will take effect on january 1, 2017, includes duexis and vimovo.  Full Article

Horizon pharma says it continues to have discussions with Express Scripts
Monday, 1 Aug 2016 03:56pm EDT 

Horizon Pharma : Continues to have discussions with express scripts and sees potential pathway to completion of potential partnership with express scripts beginning 2017 .Recognizes express scripts published formulary exclusion list, which will take effect on january 1, 2017, includes duexis and vimovo.  Full Article

More From Around the Web

Photo

Jim Chanos slams Express Scripts and Mallinckrodt over high drug prices

LAS VEGAS Noted short-seller Jim Chanos on Thursday criticized the alliance between Mallinckrodt Plc which uses the pharmacy benefits manager Express Scripts as the exclusive distributor for its drug Acthar.